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Abstract
• MUC13 and MUC16 are epithelial expressed proteins
implicated in various carcinomas. Overexpression of these
biomarkers appear to play a role in tumor growth; this
discovery has paved a road for multiple studies discussing
the potential of targeting mucin proteins and optimize
immunotherapy approaches against carcinomas.
• Our study serves to investigate the level of expression of
MUC13 and MUC16 in cancerous and normal tissue and
to discuss the implications our findings may have for the
utilization of these biomarkers for cancer therapy.

Introduction and background

Materials and Methods
• Immunohistochemistry is a laboratory method that allows the visualization of specific antigens in tissue
samples through antibody-antigen enzymatic interaction.
• We used IHC to investigate the level of protein expression of MUC13 and MUC16 in tissue microarray
with different types and stages of cancers (TMA samples of patients with confirmed cancer diagnosis
were used).
• Cancerous tissues were of pancreatic, ovarian, colon, and liver origin; samples underwent either single
or double IHC staining to detect antigen (MUC13 & MUC16) expression.
q After proper processing, samples were incubated with primary antibody (i.e., MUC13,
MUC16) overnight.
q TMAs were incubated with secondary antibody and stained using 3, 3'-diaminobenzidine
(DAB) and hematoxylin.

• Slides were analyzed using a 3D-Histech Slide Scanner; samples were visualized at 40X magnification.
• Radioimmunotherapy (RIT) is a relatively new antineoplastic therapeutic approach that combines high dose
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• Epidermal growth factor receptor (EGFR) protein is
heavily involved in cell signaling that regulates cell
mitosis, growth, and lifespan. EGFR has been extensively
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studied and identified as another prevalent tumor
biomarker.
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